Pharma In The Brave New World Of Corporatized Care
Still transforming their organizations to deal with the waning influence of the individual prescriber, pharma commercial leaders now face a new challenge: the growth of the corporate model of care, as large numbers of US physicians exchange the independence of physician-ownership for the predictability of working as employees in larger organizations. Corporate models of care, characterized by more centralized decision making, add a new dimension of customer complexity in an already tough environment.
You may also be interested in...
The company isn’t providing much detail on reasons or commercial strategy going forward, but its long-term outlook, particularly in western markets, is uninspiring, burdened by generic competition and a mixed R&D track record.
Execution, discipline, and reliance on proven sales and marketing methods helped turn around key multiple sclerosis drug Avonex, says Biogen's new EVP, Global Commercial Operations.
One year after the passage of health care reform, recommendations around some of the more far-reaching elements of the legislation are beginning to emerge. One proposal biopharmas cannot afford to ignore: Medicare sanctioned accountable care organizations.